Jingwu Zang (I-Mab)

Ab­b­Vie jumps in­to CD47 game, en­gi­neers $3B deal with am­bi­tious Chi­nese play­er

Gilead’s $4.9 bil­lion bet on Forty Sev­en ev­i­dent­ly trig­gered a rush among Big Phar­ma to look for their own drug that tar­gets the CD47 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.